CN1231468C - 化合物 - Google Patents

化合物 Download PDF

Info

Publication number
CN1231468C
CN1231468C CNB018175325A CN01817532A CN1231468C CN 1231468 C CN1231468 C CN 1231468C CN B018175325 A CNB018175325 A CN B018175325A CN 01817532 A CN01817532 A CN 01817532A CN 1231468 C CN1231468 C CN 1231468C
Authority
CN
China
Prior art keywords
methyl
phenyl
trifluoromethyl
fluoro
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018175325A
Other languages
English (en)
Chinese (zh)
Other versions
CN1483025A (zh
Inventor
朱塞普·阿尔瓦罗
罗马诺·迪法比奥
保罗·马拉格尼
马西亚·坦皮里
玛丽亚·E·特兰奎利尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN1483025A publication Critical patent/CN1483025A/zh
Application granted granted Critical
Publication of CN1231468C publication Critical patent/CN1231468C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
CNB018175325A 2000-10-17 2001-10-12 化合物 Expired - Fee Related CN1231468C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0025354.2A GB0025354D0 (en) 2000-10-17 2000-10-17 Chemical compounds
GB0025354.2 2000-10-17

Publications (2)

Publication Number Publication Date
CN1483025A CN1483025A (zh) 2004-03-17
CN1231468C true CN1231468C (zh) 2005-12-14

Family

ID=9901397

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018175325A Expired - Fee Related CN1231468C (zh) 2000-10-17 2001-10-12 化合物

Country Status (29)

Country Link
US (5) US7119092B2 (US07648990-20100119-C00006.png)
EP (4) EP1524266B1 (US07648990-20100119-C00006.png)
JP (1) JP3940359B2 (US07648990-20100119-C00006.png)
KR (1) KR100847414B1 (US07648990-20100119-C00006.png)
CN (1) CN1231468C (US07648990-20100119-C00006.png)
AR (1) AR034268A1 (US07648990-20100119-C00006.png)
AT (3) ATE355271T1 (US07648990-20100119-C00006.png)
AU (4) AU2001295723B2 (US07648990-20100119-C00006.png)
BR (1) BR0114637A (US07648990-20100119-C00006.png)
CA (1) CA2425876C (US07648990-20100119-C00006.png)
CY (1) CY1107634T1 (US07648990-20100119-C00006.png)
CZ (1) CZ299824B6 (US07648990-20100119-C00006.png)
DE (3) DE60127002T2 (US07648990-20100119-C00006.png)
DK (2) DK1524266T3 (US07648990-20100119-C00006.png)
ES (3) ES2346108T3 (US07648990-20100119-C00006.png)
GB (1) GB0025354D0 (US07648990-20100119-C00006.png)
HK (2) HK1058788A1 (US07648990-20100119-C00006.png)
HU (1) HU228146B1 (US07648990-20100119-C00006.png)
IL (3) IL155165A0 (US07648990-20100119-C00006.png)
MX (1) MXPA03003536A (US07648990-20100119-C00006.png)
MY (1) MY124957A (US07648990-20100119-C00006.png)
NO (1) NO324468B1 (US07648990-20100119-C00006.png)
NZ (1) NZ525091A (US07648990-20100119-C00006.png)
PL (1) PL203071B1 (US07648990-20100119-C00006.png)
PT (2) PT1524266E (US07648990-20100119-C00006.png)
SI (2) SI1326832T1 (US07648990-20100119-C00006.png)
TW (1) TWI299730B (US07648990-20100119-C00006.png)
WO (1) WO2002032867A1 (US07648990-20100119-C00006.png)
ZA (1) ZA200302801B (US07648990-20100119-C00006.png)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39921E1 (en) 1999-10-07 2007-11-13 Smithkline Beecham Corporation Chemical compounds
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
GB0108595D0 (en) 2001-04-05 2001-05-23 Glaxo Group Ltd Chemical compounds
GB0119797D0 (en) 2001-08-14 2001-10-03 Glaxo Group Ltd Chemical compounds
GB0203022D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
US7482365B2 (en) 2002-02-08 2009-01-27 Glaxo Group Limited Piperidylcarboxamide derivatives and their use in the treatment of tachykinin-mediated diseases
TWI283241B (en) 2002-05-29 2007-07-01 Tanabe Seiyaku Co Novel piperidine compound
JP4079727B2 (ja) * 2002-09-06 2008-04-23 セントラル硝子株式会社 光学活性１−（フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル）アルキルアミンｎ−モノアルキル誘導体とその製造方法
JO2696B1 (en) * 2002-12-23 2013-03-03 شركة جانسين فارماسوتيكا ان. في Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists
US7435736B2 (en) 2002-12-23 2008-10-14 Janssen Pharmaceutica, N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
JO2485B1 (en) 2002-12-23 2009-01-20 شركة جانسين فارماسوتيكا ان. في 1-Piperidine-3-Yl-4-Piperidine-4-Yl-Piperazine derivatives substituted and used as quinine antagonists
ATE400568T1 (de) * 2002-12-23 2008-07-15 Janssen Pharmaceutica Nv Substituierte 4-(4-piperidin-yl-piperazin-1-yl)- azepan-derivate und ihre verwendung als tachykinin-antagonisten
WO2004067093A2 (en) * 2003-01-27 2004-08-12 Glaxo Group Limited Nk1 receptor antagonists for the treatment of functional dyspepsia
FR2853648B1 (fr) * 2003-04-11 2006-08-18 Fournier Lab Sa Nouveaux derives de benzenesulfonamides et leur utilisation en therapeutique
US20040242639A1 (en) * 2003-03-31 2004-12-02 Bharat Lagu Phospholipase C inhibitors for use in treating inflammatory disorders
US20040235855A1 (en) * 2003-03-31 2004-11-25 Bharat Lagu Phospholipase C inhibitors for use in treating inflammatory disorders
WO2004087654A2 (en) * 2003-03-31 2004-10-14 Janssen Pharmaceutica N.V. Phospholipase c inhibitors for use in treating inflammatory disorders
GB0308968D0 (en) * 2003-04-17 2003-05-28 Glaxo Group Ltd Medicaments
ES2307025T3 (es) * 2003-06-10 2008-11-16 Janssen Pharmaceutica Nv Combinacion de opioides y un derivado de la piperazina para el tratamiento del dolor.
MXPA05013770A (es) * 2003-06-19 2006-03-08 Pfizer Prod Inc Antagonista de neuroquinina 1.
JO2525B1 (en) * 2004-04-08 2010-03-17 شركة جانسين فارماسوتيكا ان. في Derived 4-alkyl-and-4-canoelperidine derivatives and their use as anti-neroquin
WO2006062110A1 (ja) * 2004-12-06 2006-06-15 Banyu Pharmaceutical Co., Ltd. ピペラジン誘導体
GB0426942D0 (en) * 2004-12-08 2005-01-12 Glaxo Group Ltd Medicament
ES2350647T3 (es) 2005-03-08 2011-01-25 Janssen Pharmaceutica Nv Derivados de diaza-espiro-[4.4]-nonano como antagonistas de neuroquininas (nk1).
GB0514704D0 (en) * 2005-07-18 2005-08-24 Glaxo Group Ltd Chemical compounds
GB0514707D0 (en) * 2005-07-18 2005-08-24 Glaxo Group Ltd Chemical compounds
GB0514705D0 (en) * 2005-07-18 2005-08-24 Glaxo Group Ltd Chemical compounds
JP4904945B2 (ja) 2006-06-30 2012-03-28 セントラル硝子株式会社 光学活性１−（フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル）アルキルアミンｎ−モノアルキル誘導体の製造方法
EP2129381A1 (en) 2007-01-24 2009-12-09 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
AU2008299921B2 (en) 2007-09-13 2012-03-01 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
GB0812849D0 (en) * 2008-07-14 2008-08-20 Glaxo Wellcome Mfg Pte Ltd Novel compounds
ES2672099T3 (es) 2011-07-04 2018-06-12 Irbm - Science Park S.P.A. Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal
KR20140122764A (ko) 2012-02-22 2014-10-20 레오 파마 에이/에스 신규한 뉴로키닌 1 수용체 길항제 화합물
WO2015024203A1 (en) * 2013-08-20 2015-02-26 Leo Pharma A/S Novel neurokinin 1 receptor antagonist compounds ii
AU2018251604B2 (en) 2017-04-10 2022-04-14 Chase Therapeutics Corporation NK1-antagonist combination and method for treating synucleinopathies
EP3645120A4 (en) 2017-06-30 2021-03-24 Chase Pharmaceuticals Corporation NK-1 ANTAGONIST COMPOSITIONS AND METHODS OF USE IN THE TREATMENT OF DEPRESSION
CN111116514B (zh) * 2020-01-10 2024-03-19 广州科锐特生物科技有限公司 一种1-环丙甲酰基哌嗪盐酸盐的制备方法

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US536020A (en) * 1894-04-09 1895-03-19 Washing or bathing apparatus
US4110327A (en) * 1974-05-09 1978-08-29 Toyama Chemical Co., Ltd. 2,3 Diketo-piperazinocarbonylamino alkanoic acids and derivatives
US4379152A (en) * 1974-05-09 1983-04-05 Toyama Chemical Co., Ltd. Cephalosporins
US4087424A (en) * 1974-05-09 1978-05-02 Toyama Chemical Co., Ltd. Novel penicillins and cephalosporins and process for producing the same
US4410522A (en) * 1974-05-09 1983-10-18 Toyama Chemical Co., Ltd. Cephalosporins
IL47168A (en) 1974-05-09 1979-07-25 Toyama Chemical Co Ltd Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same
US4112090A (en) * 1974-05-09 1978-09-05 Toyama Chemical Co., Ltd. Novel penicillins and cephalosporins and process for producing the same
US4327097A (en) * 1974-05-09 1982-04-27 Toyama Chemical Co., Ltd. Novel penicillins
US4219554A (en) * 1974-05-09 1980-08-26 Toyama Chemical Company, Limited Novel penicillins and cephalosporins and process for producing same
NO154582C (no) * 1978-10-20 1986-11-05 Ferrosan Ab Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider.
JPS57118587A (en) 1981-11-26 1982-07-23 Toyama Chem Co Ltd Novel penicillin
US5028610A (en) * 1987-03-18 1991-07-02 Sankyo Company Limited N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use
GB8709666D0 (en) 1987-04-23 1987-05-28 Beecham Group Plc Compounds
GB8713061D0 (en) 1987-06-04 1987-07-08 Beecham Group Plc Compounds
US5109014A (en) * 1990-12-10 1992-04-28 Jacobson Richard M N-aryl-3-aryl-4-substituted-2,3,4,5-tetrahydro-1H-pyrazole-1-carboxamides
SE9100860D0 (sv) 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
ES2149767T5 (es) * 1991-09-20 2005-06-16 Glaxo Group Limited Nuevo uso medico para antagonistas de taquiquininas.
EP0545478A1 (en) * 1991-12-03 1993-06-09 MERCK SHARP & DOHME LTD. Heterocyclic compounds as tachykinin antagonists
US5334387A (en) * 1993-02-23 1994-08-02 Colgate-Palmolive Company Topical composition comprising mono and dialkyl phosphates with a cosurfactant
US5563127A (en) * 1993-03-24 1996-10-08 The Dupont Merck Pharmaceutical Company Boronic acid and ester inhibitors of thrombin
US5348955A (en) * 1993-06-22 1994-09-20 Merck & Co., Inc. N,N-diacylpiperazines
EP0655422B1 (de) 1993-11-26 1998-08-12 Deutsche Rockwool Mineralwoll-GmbH Verfahren zum Herstellen einer Schmelze für die Mineralfaserherstellung
IL111730A (en) * 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them
TW385308B (en) * 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
CA2171850A1 (en) 1994-07-15 1996-02-01 Kiyoaki Katano Novel compound having platelet aggregation inhibitor effect
DE4425146A1 (de) * 1994-07-15 1996-01-18 Basf Ag Verwendung heterocyclischer Verbindungen
AU3085895A (en) 1994-07-26 1996-02-22 Sankyo Company Limited N-phenylated amide and urea derivatives
US5696123A (en) * 1994-09-17 1997-12-09 Boehringer Ingelheim Kg Neurokinin antagonists
DE19520499C2 (de) * 1994-09-17 2003-06-18 Boehringer Ingelheim Kg Neurokinin-Antagonisten, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende pharmazeutische Zusammensetzungen sowie ihre Verwendung
JPH10506399A (ja) * 1994-09-30 1998-06-23 ノバルティス アクチェンゲゼルシャフト １−アシル−４−マリファチルアミノピペリジン化合物
US5998444A (en) * 1995-10-24 1999-12-07 Zeneca Ltd. Piperidinyl compounds as NK1 or NK2 antagonists
DE69534213T2 (de) * 1994-10-25 2006-01-12 Astrazeneca Ab Therapeutisch wirksame Heterocyclen
US5629322A (en) 1994-11-15 1997-05-13 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
EE9700141A (et) 1994-12-23 1997-12-15 Dr. Karl Thomae Gmbh Piperasiinderivaadid, neid sisaldavad ravimid, nende kasutamine ja valmistamise meetod
US5700801A (en) 1994-12-23 1997-12-23 Karl Thomae, Gmbh Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
NZ321575A (en) * 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
DE19608665A1 (de) 1996-03-06 1997-09-11 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US6057323A (en) * 1996-03-08 2000-05-02 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
WO1997036593A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997036888A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5859012A (en) 1996-04-03 1999-01-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU707139B2 (en) 1996-04-03 1999-07-01 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU3359697A (en) 1996-07-08 1998-02-02 Yamanouchi Pharmaceutical Co., Ltd. Bone resorption inhibitors
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
US5929077A (en) 1996-11-08 1999-07-27 Leftheris; Katerina Thioproline-containing inhibitors of farnesyl protein transferase
US6114315A (en) * 1996-12-02 2000-09-05 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
JP2001504852A (ja) * 1996-12-02 2001-04-10 メルク シヤープ エンド ドーム リミテツド 双極性障害の治療のためのｎｋ−１受容体拮抗薬の使用
US5977104A (en) * 1996-12-02 1999-11-02 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating bipolar disorders
AUPO735997A0 (en) 1997-06-17 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
EP1014984A1 (en) 1997-08-27 2000-07-05 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
EP1034164B1 (en) 1997-11-24 2004-05-19 Merck & Co., Inc. Substituted beta-alanine derivatives as cell adhesion inhibitors
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
US6253732B1 (en) * 1999-11-11 2001-07-03 Ford Global Technologies, Inc. Electronic throttle return mechanism with a two-spring and two-lever default mechanism
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
US20030022891A1 (en) 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
GB0203022D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
MY141736A (en) 2002-10-08 2010-06-15 Elanco Animal Health Ireland Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists

Also Published As

Publication number Publication date
HUP0301459A2 (en) 2006-09-28
US20100081667A1 (en) 2010-04-01
EP1524266B1 (en) 2007-02-28
EP1524266A1 (en) 2005-04-20
KR20030036932A (ko) 2003-05-09
DK1326832T3 (da) 2005-01-31
IL191486A0 (en) 2008-11-03
ES2282794T3 (es) 2007-10-16
JP3940359B2 (ja) 2007-07-04
US20040014770A1 (en) 2004-01-22
DE60106287D1 (de) 2004-11-11
JP2004511544A (ja) 2004-04-15
AU2005204234A1 (en) 2005-09-15
CN1483025A (zh) 2004-03-17
WO2002032867A1 (en) 2002-04-25
ES2346108T3 (es) 2010-10-08
MXPA03003536A (es) 2003-08-07
EP1326832A1 (en) 2003-07-16
IL155165A0 (en) 2003-10-31
ZA200302801B (en) 2004-04-21
NO324468B1 (no) 2007-10-22
AU2001295723B2 (en) 2005-05-26
AU2009201407B2 (en) 2011-12-15
US20060142302A1 (en) 2006-06-29
ES2227287T3 (es) 2005-04-01
CA2425876C (en) 2009-07-07
PT1326832E (pt) 2005-01-31
PT1524266E (pt) 2007-05-31
US20050137208A1 (en) 2005-06-23
US7060702B2 (en) 2006-06-13
TWI299730B (en) 2008-08-11
DK1524266T3 (da) 2007-06-25
US7294630B2 (en) 2007-11-13
PL203071B1 (pl) 2009-08-31
HUP0301459A3 (en) 2007-11-28
AU9572301A (en) 2002-04-29
BR0114637A (pt) 2003-09-30
DE60106287T2 (de) 2006-02-23
US20080021041A1 (en) 2008-01-24
NZ525091A (en) 2005-04-29
GB0025354D0 (en) 2000-11-29
ATE355271T1 (de) 2006-03-15
EP1921064A1 (en) 2008-05-14
AU2009201407A1 (en) 2009-05-07
EP1752449A1 (en) 2007-02-14
KR100847414B1 (ko) 2008-07-18
DE60142197D1 (de) 2010-07-01
IL155165A (en) 2008-11-26
EP1326832B1 (en) 2004-10-06
CA2425876A1 (en) 2002-04-25
HU228146B1 (en) 2012-12-28
US7119092B2 (en) 2006-10-10
DE60127002T2 (de) 2007-10-31
US7648990B2 (en) 2010-01-19
ATE468324T1 (de) 2010-06-15
HK1075889A1 (en) 2005-12-30
AR034268A1 (es) 2004-02-18
SI1326832T1 (en) 2005-02-28
CZ20031082A3 (cs) 2004-08-18
AU2005204234B2 (en) 2009-05-07
MY124957A (en) 2006-07-31
SI1524266T1 (sl) 2007-08-31
NO20031561D0 (no) 2003-04-07
NO20031561L (no) 2003-06-14
CY1107634T1 (el) 2013-04-18
HK1058788A1 (en) 2004-06-04
PL361180A1 (en) 2004-09-20
DE60127002D1 (de) 2007-04-12
CZ299824B6 (cs) 2008-12-03
ATE278669T1 (de) 2004-10-15
EP1921064B1 (en) 2010-05-19

Similar Documents

Publication Publication Date Title
CN1231468C (zh) 化合物
CN1319973C (zh) 哌啶衍生物
CN1067071C (zh) 咔啉衍生物
CN1027588C (zh) N-苯烷基取代的α-氨基羧基酰胺衍生物的制备方法
CN1142161C (zh) 作为5－ht4受体拮抗剂的二氢苯并二噁烯羧酰胺与酮衍生物
CN1227241C (zh) 具有5－羟色胺1a受体活性的芳基哌嗪类化合物
CN1741999A (zh) 用作GSK－3β抑制剂的哒嗪酮衍生物
CN1120838A (zh) 治疗局部缺血和相关疾病的杂环衍生物
CN1805938A (zh) 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
CN1934091A (zh) 治疗神经变性障碍的咪唑化合物
CN1391564A (zh) 化合物
CN1555260A (zh) 氨基烷基取代的芳族二环化合物、它们的制备方法和它们作为药物的用途
CN1298391A (zh) 1－[(1－取代－4－哌啶基)甲基]－4－哌啶衍生物、其生产方法、含有该化合物的药物组合物和这些化合物的中间体
CN1152030C (zh) 新的杂环化合物
CN1270585A (zh) 取代的1,2,3,4－四氢化萘衍生物
CN1308324C (zh) 作为α－1肾上腺素能拮抗剂的喹唑啉衍生物
CN1859914A (zh) 苯基吡咯烷醚速激肽受体拮抗剂
CN1934081A (zh) 新型(亚)苄基－内酰胺衍生物
CN1809545A (zh) N－苯基－哌嗪衍生物和预防或者治疗5HT2c受体相关疾病的方法
CN1022914C (zh) 新的1，3-二取代哌啶衍生物的制备方法
CN1809558A (zh) 作为5ht4－拮抗剂的4－(氨甲基)－哌啶苯甲酰胺
CN1884262A (zh) 4－氨基哌啶类化合物及其医药用途
CN1117092C (zh) 氮杂双环化合物,其药物组合物及医药用途
CN1774245A (zh) 用于视网膜神经疾病的含有烷基醚衍生物或其盐的预防剂/治疗剂
CN1225465C (zh) 新化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20051214

Termination date: 20181012

CF01 Termination of patent right due to non-payment of annual fee